📊 NBIX Key Takeaways
Is Neurocrine Biosciences Inc. (NBIX) a Good Investment?
Neurocrine demonstrates exceptional financial health with 21.4% revenue growth, fortress-like balance sheet (zero debt, $713M cash), and outstanding free cash flow generation ($748.7M, 26.2% margin). The company's combination of strong top-line growth, 21.6% operating margins, and robust cash conversion provides excellent financial flexibility for biotech R&D investment and shareholder returns.
Strong 21%+ revenue growth, double‑digit operating and net margins, and a debt‑free, highly liquid balance sheet underscore sound fundamentals. Despite flat net income YoY, cash generation is robust (26% FCF margin), supporting continued R&D and commercialization without balance‑sheet strain.
Why Buy Neurocrine Biosciences Inc. Stock? NBIX Key Strengths
- Exceptional free cash flow generation of $748.7M with 26.2% FCF margin, demonstrating high-quality revenue
- Zero long-term debt with $713M cash position and 3.39x current ratio provides fortress balance sheet for biotech operations
- Strong 21.4% YoY revenue growth with 21.6% operating margin and 16.7% net margin showing profitable scaling
- EPS growth of 41.9% YoY despite flat net income indicates disciplined capital allocation through share buybacks
- Rapid topline growth with solid operating margin (21.6%)
- Debt-free, excellent liquidity (3.39x current) and massive interest coverage
- Strong cash generation ($783M OCF; 26% FCF margin)
NBIX Stock Risks: Neurocrine Biosciences Inc. Investment Risks
- Net income flat YoY (+0.0%) despite 21.4% revenue growth suggests rising operating costs or one-time charges requiring investigation
- Biotech sector exposure to regulatory risk, drug development failures, patent expirations, and clinical trial outcomes
- Operating margin sustainability uncertain if R&D expenses increase or product revenue declines
- Flat net income YoY suggests rising costs or one‑offs
- Biopharma regulatory/reimbursement and product concentration risk
- Gross margin not reported, reducing cost-structure visibility
Key Metrics to Watch
- Net income growth trajectory relative to revenue growth for signs of margin compression
- Operating cash flow sustainability and capital allocation decisions (R&D spending, M&A activity)
- Product pipeline advancement and regulatory approval status for revenue growth drivers
- Operating margin trend and R&D/SG&A as % of revenue
- Free cash flow margin and OCF growth vs. revenue
Neurocrine Biosciences Inc. (NBIX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 26.2% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.39x current ratio provides a solid financial cushion.
NBIX Profit Margin, ROE & Profitability Analysis
NBIX vs Healthcare Sector: How Neurocrine Biosciences Inc. Compares
How Neurocrine Biosciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Neurocrine Biosciences Inc. Stock Overvalued? NBIX Valuation Analysis 2026
Based on fundamental analysis, Neurocrine Biosciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Neurocrine Biosciences Inc. Balance Sheet: NBIX Debt, Cash & Liquidity
NBIX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Neurocrine Biosciences Inc.'s revenue has grown significantly by 152% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.47 reflects profitable operations.
NBIX Revenue Growth, EPS Growth & YoY Performance
NBIX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $622.1M | $129.8M | $1.24 |
| Q2 2025 | $590.2M | $65.0M | $0.63 |
| Q1 2025 | $515.3M | $7.9M | $0.08 |
| Q3 2024 | $498.8M | $83.1M | $0.82 |
| Q2 2024 | $452.7M | $18.9M | $0.19 |
| Q1 2024 | $420.4M | $43.4M | $0.42 |
| Q3 2023 | $387.9M | $65.5M | $0.67 |
| Q2 2023 | $378.2M | -$3.0M | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Neurocrine Biosciences Inc. Dividends, Buybacks & Capital Allocation
NBIX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Neurocrine Biosciences Inc. (CIK: 0000914475)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NBIX
What is the AI rating for NBIX?
Neurocrine Biosciences Inc. (NBIX) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NBIX's key strengths?
Claude: Exceptional free cash flow generation of $748.7M with 26.2% FCF margin, demonstrating high-quality revenue. Zero long-term debt with $713M cash position and 3.39x current ratio provides fortress balance sheet for biotech operations. ChatGPT: Rapid topline growth with solid operating margin (21.6%). Debt-free, excellent liquidity (3.39x current) and massive interest coverage.
What are the risks of investing in NBIX?
Claude: Net income flat YoY (+0.0%) despite 21.4% revenue growth suggests rising operating costs or one-time charges requiring investigation. Biotech sector exposure to regulatory risk, drug development failures, patent expirations, and clinical trial outcomes. ChatGPT: Flat net income YoY suggests rising costs or one‑offs. Biopharma regulatory/reimbursement and product concentration risk.
What is NBIX's revenue and growth?
Neurocrine Biosciences Inc. reported revenue of $2.9B.
Does NBIX pay dividends?
Neurocrine Biosciences Inc. does not currently pay dividends.
Where can I find NBIX SEC filings?
Official SEC filings for Neurocrine Biosciences Inc. (CIK: 0000914475) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NBIX's EPS?
Neurocrine Biosciences Inc. has a diluted EPS of $4.67.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NBIX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Neurocrine Biosciences Inc. has a BUY rating with 84% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is NBIX stock overvalued or undervalued?
Valuation metrics for NBIX: ROE of 14.7% (sector avg: 15%), net margin of 16.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NBIX stock in 2026?
Our dual AI analysis gives Neurocrine Biosciences Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is NBIX's free cash flow?
Neurocrine Biosciences Inc.'s operating cash flow is $782.7M, with capital expenditures of $34.0M. FCF margin is 26.2%.
How does NBIX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 16.7% (avg: 12%), ROE 14.7% (avg: 15%), current ratio 3.39 (avg: 2).